Catecholamines in urine, blood and cerebrospinal fluid

  • H. Wisser
  • D. Ratge
Part of the Key Topics in Brain Research book series (KEYTOPICS)


Quantification of catecholamines in body fluids such as urine, blood and cerebrospinal fluid is one way—beside the determination of receptor densities and/or the stimulation of the cAMP-system—of evaluating the activity of the sympathetic nervous system. In the following discourse the analytical problems and then the clinical importance of the determination of catecholamines in different specimens will be discussed.


High Performance Liquid Chromatography Amyotrophic Lateral Sclerosis Plasma Noradrenaline Concentration Lumbar Spinal Fluid Radioenzymatic Method 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bauersfeld W, Ratge D, Knoll E, Wisser H (1986) Determination of catecholamines in plasma by HPLC and amperometric detection. Comparison with a radioenzymatic method. J Clin Chem Clin Biochem 24: 185–188PubMedGoogle Scholar
  2. Bravo LE (1986) Plasma catecholamines: their measurement and clinical utility. Lab Med 17: 512–516Google Scholar
  3. Chase ThN, Eng N, Gordon EK (1976) Biochemical aids in the diagnosis of Parkinson’s disease. Ann Clin Lab Sci 6: 4–10PubMedGoogle Scholar
  4. Gibson CJ, Logen M, Growdon JH (1985) CSF monoamine metabolite levels in Alzheimer’s and Parkinson’s disease. Arch Neurol 42: 489–492PubMedCrossRefGoogle Scholar
  5. Goldstein DS, Lake RC (1984) Plasma norepinephrine and epinephrine levels in essential hypertension. Fed Proc 43: 57–61PubMedGoogle Scholar
  6. Hjemdahl P (1984) Inter-laboratory comparison of plasma catecholamine determinations using several different assays. Acta Physiol Scand [Suppl] 527: 43–54Google Scholar
  7. Hoehn MM, Crowley ThJ, Rutledge ChO (1977) The Parkinsonian syndrome and its dopamine correlates. Adv Exp Med Biol 90: 243–254PubMedGoogle Scholar
  8. Markianos M, Hadjikonstantinou M, Bistolaki E (1982) Urinary nor-adrenaline and serotonin metabolites in drug free Parkinson patients and the effect of L-dopa treatment. Acta Neurol Scandinav 66: 267–275CrossRefGoogle Scholar
  9. Pinessi L, Rainero I, de Gennaro T, Gentile S, Portaleone P, Bergamasco B (1987) Biogenic amines in cerebrospinal fluid and plasma of patients with dementia of Alzheimer type. Function Neurol 2: 51–58Google Scholar
  10. Ratge D, Wisser H (1983) Praeanalytik and Analytik der Katecholamine. Ärztl Lab 29: 209–214Google Scholar
  11. Turkka JT, Juujärvi KK, Lapinlampi TO, Myllylä VV (1986) Serum nor-adrenaline response to standing up in patients with Parkinson’s disease. Europ Neurol 25: 355–361PubMedCrossRefGoogle Scholar
  12. Turkka JT, Juujärvi KK, Lapinlampi TO, Myllylä W (1987) Correlation of autonomic dysfunction to CSF concentrations of noradrenaline and 3methoxy 4-hydroxyphenylglycol in Parkinson’s disease. Europ Neurol 26: 29–34PubMedCrossRefGoogle Scholar
  13. Wood JH (1980) Neurochemical analysis of cerebrospinal fluid. Neurology 30: 645–651PubMedGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1989

Authors and Affiliations

  • H. Wisser
    • 1
  • D. Ratge
    • 1
  1. 1.Department of Clinical ChemistryRobert-Bosch-KrankenhausStuttgartFederal Republic of Germany

Personalised recommendations